CASP2 and cancer: In cancer cells, BCL9L dysfunction results in lower levels of caspase-2, and when chromosome missegregation occurs this deficiency results in suboptimal activation of caspase-2, leading to impaired p53 stabilization, tBID formation, and attenuated cell death.